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Background: Guidelines advise the use of antibacterials (ABs) in the management of COPD exacerbations.
COPD patients often have multiple comorbidities, such as diabetes mellitus and cardiac diseases, leading to poly-
pharmacy. Consequently, drug–drug interactions (DDIs) may frequently occur, and may cause serious adverse
events and treatment failure.
Objectives: (i) To review DDIs related to frequently prescribed ABs among COPD patients from observational
and clinical studies. (ii) To improve AB prescribing safety in clinical practice by structuring DDIs according to
comorbidities of COPD.
Methods: We conducted a systematic review by searching PubMed and Embase up to 8 February 2018 for clinic-
al trials, cohort and case–control studies reporting DDIs of ABs used for COPD. Study design, subjects, sample
size, pharmacological mechanism of DDI and effect of interaction were extracted. We evaluated levels of DDIs
and quality of evidence according to established criteria and structured the data by possible comorbidities.
Results: In all, 318 articles were eligible for review, describing a wide range of drugs used for comorbidities
and their potential DDIs with ABs. DDIs between ABs and co-administered drugs could be subdivided into:
(i) co-administered drugs altering the pharmacokinetics of ABs; and (ii) ABs interfering with the pharmacokinetics
of co-administered drugs. The DDIs could lead to therapeutic failures or toxicities.
Conclusions: DDIs related to ABs with clinical significance may involve a wide range of indicated drugs to treat
comorbidities in COPD. The evidence presented can support (computer-supported) decision-making by health
practitioners when prescribing ABs during COPD exacerbations in the case of co-medication.
Introduction
COPD is a complex respiratory disorder characterized by persistent
respiratory symptoms and airflow limitation.1 The chronic and pro-
gressive course of COPD is frequently aggravated by exacerbation,
defined as an acute worsening of respiratory symptoms, such as
increased cough, dyspnoea and production of sputum.2
Exacerbations of COPD can be triggered by respiratory tract infec-
tions; 40%–60% of exacerbations are caused by bacteria, especial-
ly Haemophilus influenzae, Streptococcus pneumoniae and
Moraxella catarrhalis.3 Evidence from randomized controlled trials
VC The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
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indicated that use of antibacterials (ABs) may reduce the fre-
quency and severity of COPD exacerbations.4–6 Therefore, guide-
lines have recommended involving ABs in the therapeutic and
preventive management of COPD exacerbations.1,7
Patients with COPD often suffer from multiple morbidities.8
Hence, polypharmacy is common and contributes to drug–drug
interactions (DDIs). Adverse drug reactions (ADRs) or therapeutic
failure may be the result of interactions between ABs and co-
administered drugs. In addition, COPD is an age-related disease
and the elderly are more susceptible to the effect of DDIs because
of gradual physiological changes affecting pharmacokinetics and
pharmacodynamics.9
The objectives of this study were to: (i) systematically review
DDIs related to frequently prescribed ABs among COPD patients
from observational and clinical studies; and (ii) improve AB pre-
scribing safety in clinical practice by structuring DDIs according to
comorbidities of COPD. Studies without comparison groups, and
therefore with low quality of the causal evidence, such as case
reports about QT-interval prolonging interactions, are not included
in this review. A DDI handbook such as Stockley’s Drug Interactions
and the official product information should be referred to for the
clinical impact of these kinds of interaction.
Methods
Search strategy
We conducted a systematic review following the PRISMA guideline.
PubMed and Embase databases were searched for related articles pub-
lished in English up to 8 February 2018 using key terms ‘drug interactions’,
‘pharmacokinetics’ and ‘pharmacodynamics’, and a list of most frequently
used ABs for COPD (Table 1). The ABs were selected based on two related
Cochrane reviews and their prescription frequency in the University of
Groningen prescription database IADB.nl (http://www.iadb.nl/) covering
drug prescriptions for700000 people.4,5 Additionally, we checked the pri-
mary sources of signals from Dutch DDI alert systems: G-Standard and
Pharmabase.10 Reference lists from eligible studies were also tracked for
additional qualified papers. Full search details are provided in the
Supplementary data, available at JAC Online.
Study selection criteria
Eligible studies met the following criteria: (i) DDIs in humans; (ii) involving
the targeted ABs; and (iii) being clinical trials, randomized controlled trials
or cohort or case–control studies. We excluded case reports and other
descriptive studies. We further excluded studies with subjects whose
pharmacokinetics and pharmacodynamics were not comparable to those
of general COPD patients, e.g. newborn babies, pregnant women and
patients with severe renal/hepatic impairment. Other exclusion criteria
were: (i) unregistered drugs (by FDA or EMA); (ii) involving three or more
drug interactions; and (iii) not DDIs (food–drug or gene–drug interactions);
(iv) not original studies (reviews, letters and editorials). Pharmacodynamic
interactions were beyond the scope of this review and were excluded.
Data extraction and quality assessment
All records were exported to Refworks; titles and abstracts were screened
by Y. W. and A. M. E. J. independently. Full-text papers were obtained for
records that were considered of potential relevance by at least one of the
reviewers. Final decisions were made by consensus between two reviewers
according to the preset criteria. Discrepancies between reviewers were
resolved by discussion; a third reviewer (E. H.) was asked if no consensus
was reached. Information about names of ABs and related interacting
drugs, study design, study subjects, sample size, interacting mechanism,
effects of interaction and recommendation by study authors were
extracted by the same reviewers (Y. W. and A. M. E. J.) and checked by an-
other reviewer (M. A. B.). Quality of evidence was evaluated by grading 0–4
based on criteria (Table 2) used by previous studies.11,12
The strengths of the DDIs were classified into four levels (1, strong; 2,
substantial; 3, moderate; 4, weak/no) according to preset published criteria
(Table 3).12 In the cases of several studies on the same DDI combination,
we categorized the DDI based on the highest level of severity. Considering
that drugs with a narrow therapeutic index (NTI) are more vulnerable to
DDIs, the strength of the DDI for such drugs was upgraded one level.12
Results
Publications identified by literature search
Our search yielded 1412 and 1734 studies from PubMed and
Embase, respectively (Figure 1). After removing duplicates, 2560
articles were screened by title and abstract, of which 630 papers
were included for full-text screening, resulting in 282 eligible
articles. With 36 studies identified from other resources, we finally
obtained 318 studies for assessment in this review.
The interacting drugs, underlying mechanisms, levels and prac-
tice recommendations for the DDIs are presented in Table 4.
Details on individual studies of DDIs with a potential clinical signifi-
cance (levels 1–3) are presented in Tables S1 and S2 and the data
on studies with a low level of DDIs (weak or no interaction) are pre-
sented in Table S3.
Table 1. ABs included in the study that are frequently prescribed among COPD patientsa
Category Sub-category ABs included
b-Lactam penicillin amoxicillin/clavulanic acid (co-amoxiclav), amoxicillin, flucloxacillin, pheneticillin, phenoxymethylpenicillin (penicillin V)
cephalosporin cefaclor, cefuroxime, ceftriaxone, cefradine, ceftazidime
Macrolide erythromycin, clarithromycin, azithromycin, roxithromycin, clindamycin
Tetracycline tetracycline, doxycycline, minocycline
Quinolone fluoroquinolone ciprofloxacin, moxifloxacin, levofloxacin, ofloxacin, norfloxacin
other quinolone pipemidic acid
Sulphonamide sulfamethoxazole
Others nitrofurantoin, methenamine, trimethoprim
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We present a step-by-step approach to AB prescribing in COPD:
(i) check whether co-morbidity is present; (ii) a quick overview of
the AB and its interacting medication, possible interaction mech-
anism, level of interaction, and practical recommendations is pro-
vided in Table 4; and (iii) detailed explanation about related
interacting mechanisms and recommendations for the manage-
ment of related DDIs are provided in the main text.
Mechanisms of DDI
An AB can act as an inhibitor/inducer and/or a substrate, producing
moderate to strong DDI with other co-administered medication.
There are two scenarios: (i) the co-administered drug alters the
pharmacokinetic parameters of the AB; and (ii) the AB influences
the pharmacokinetic parameters of the co-administered medica-
tion. The main mechanisms of these DDIs are complex formation,
inhibition/induction of drug-metabolizing enzymes and alteration
of drug transporters (Table 4). The ability to inhibit CYP3A4 makes
ABs prone to interaction with many different drugs as CYP3A4
metabolizes .50% of clinically prescribed drugs.13
Information structured according to drugs for
comorbidities
The presentation of information on potential clinically significant
DDIs with a moderate to strong level of interaction is according to
the most frequent comorbidities that have been reported in COPD
patients.8,14 Potential mechanisms of DDIs and actionable recom-
mendations to manage the DDIs are provided in Table 4.
Diabetes
Patients with COPD have a 50% higher risk of developing diabetes
than persons without COPD.15 Some antidiabetic drugs are
Table 2. Quality of evidence for DDIs11,12
Definition Score
Clinical research with appropriate control group and relevant pharmacokinetics and/or pharmacodynamic parameters. The studies meet all of
the criteria below:
• The interacting effect of concomitant medication with investigated drugs is reported in the manuscript.
• All potential confounders are mentioned and taken into account (for example smoking behaviour or renal function).
• The results of interaction are based on the steady-state kinetics.
• Variation in dose was adjusted.
4
Clinical research with appropriate control group and relevant pharmacokinetics and/or pharmacodynamic parameters that does not meet one
or more of the pre-defined criteria above.
3
Complete observational studies with clinically relevant results. 2
Incomplete observational studies. (e.g. without controlling confounders or presence of other explanatory factors for the adverse reaction),
case reports, summary of product characteristics.
1
In vitro studies, in vivo animal studies, prediction modelling studies. 0
Table 3. Description of level of DDIs10
Definition AUC Clearance Scorea
Involved inhibitor .200% " # .67% 1
Involved inducer .90% # " 900% 1
For observational studies, RR/OR10 1
Involved inhibitor 75%–200% " # 43% to ,67% 2
Involved inducer 60%–90% # " 150% to ,900% 2
For observational studies, RR/OR 3–9 2
Involved inhibitor 25%–75% " # 20% to ,43% 3
Involved inducer 25%–60% # " 33% to ,150% 3
For observational studies, RR/OR 1.5–2.9 3
Involved inducer/inhibitor ,25% change # ,20% or " ,33% 4
For observational studies, RR/OR ,1.5 4
(a) For interacting drugs with an NTI, the
degree of DDIs will be improved to the level one higher
exception
(b) If the DDI level cannot be judged by the above
criteria, we assessed it by discussion based
on available data and evidence
exception
RR, relative risk; OR, odds ratio; ", increase; #, decrease.
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substrates of enzymes such as CYP3A4 (glipizide, tolbutamide),
CYP2C9 (glipizide, glyburide) and CYP2C8 (repaglinide), and sub-
strates of drug transporter-like P-glycoprotein (P-gp) transporter (gli-
pizide, glyburide).16–26 ABs such as clarithromycin (CYP3A4 and P-gp
inhibitor), trimethoprim/sulfamethoxazole (CYP2C8/2C9 inhibitor)
and levofloxacin (P-gp inhibitor) may inhibit the function of these
metabolic enzymes and transporters. These ABs can potentially in-
crease the blood concentration of the antidiabetic agents mentioned
above.16–26 Consequently, patients may develop hypoglycaemia.
Therefore, it is suggested that these combinations should be avoided
by substituting a related AB or adjusting the dose of antidiabetic
agents as well as monitoring the patients’ blood glucose.
Heart and circulatory system diseases
Antihypertensive agents. Hypertension is associated with COPD
with a relative risk of 1.6.15 Antihypertensive calcium channel
blockers (CCBs) such as diltiazem and verapamil are CYP3A4 sub-
strates.27–29 Therefore, macrolides (CYP3A4 inhibitors) can en-
hance the pharmacological activity of CCBs.30 Avoiding the
combination by replacement of macrolides or CCBs with another
group of drugs or adjusting the dose of CCBs while monitoring
blood pressure is recommended. Erythromycin and clarithromycin
are the most potent CYP3A4 inhibitors, while azithromycin and rox-
ithromycin are weak inhibitors.30,31 Hence, if prescribing macro-
lides, choosing macrolides with minimal inhibitory capacity to be
co-prescribed with CCBs may minimize the risk of DDI.
Spironolactone, a potassium-sparing diuretic, is used to lower
blood pressure. Combination of spironolactone with trimethoprim/
sulfamethoxazole may produce hyperkalaemia because both
drugs can inhibit renal excretion of potassium.32 Therefore, avoid-
ing this combination (by selecting an alternative AB) or adjusting
the dose of spironolactone and closely monitoring potassium
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Lipid-lowering drugs. Lipid metabolism problems are among the
most prevalent comorbidities in COPD patients.14 The main pharma-
cological approach to the management of blood cholesterol levels is
statin therapy.33 Some ABs increase the plasma concentration of
statins by several mechanisms. Statins such as simvastatin and
atorvastatin are biodegraded by CYP3A4.34,35 Therefore, potent
CYP3A4 inhibitors (erythromycin and clarithromycin) increase the
risk of statin-related side effects such as rhabdomyolysis.34,35 Other
statins, such as rosuvastatin, pravastatin and fluvastatin, are not
CYP3A4 substrates.36 However, the hepatic clearance of these sta-
tins is facilitated by anion-transporting polypeptides.37 These influx
transporters facilitate the transport of statins from systemic blood
to liver cells to be metabolized or subsequently delivered into the
bile for elimination.37 Clarithromycin and erythromycin have been
reported to be inhibitors of these transporters.38 Therefore, replacing
erythromycin and clarithromycin with other ABs, temporarily stop-
ping statins or adjusting the dose of statins while monitoring statin-
related side effects is recommended.
Oral anticoagulants. Both coumarins and direct oral anticoagu-
lants (DOACs) may interact with ABs. Multiple studies reported that
DDIs between ABs and coumarins (warfarin, phenprocoumon, ace-
nocoumarol) led to increased risks of haemorrhage.39–58 Several
interaction mechanisms were proposed.59,60 One mechanism is by
disruption of intestinal flora that synthesizes vitamin K, as many
ABs could alter the balance of gut flora.59 Another mechanism is
that ABs (e.g. trimethoprim/sulfamethoxazole and macrolides)
alter coumarin metabolism, which mainly involves CYP2C9 (tri-
methoprim/sulfamethoxazole) and CYP3A4 (macrolides).60
Therefore, to choose alternative ABs or, if not possible, to monitor
international normalized ratio (INR) values and adjust the dose of
coumarins is recommended.
DOACs are regarded as a safe alternative to replace coumar-
ins.61 However, since some DOACs (edoxaban, rivaroxaban,
dabigatran) are substrates of CYP3A4 and/or the P-gp trans-
porter, their AUC values can be increased by ABs such as
macrolides.62,63 Therefore, when macrolides and DOACs are
required in combination, careful monitoring of signs of bleeding
is needed, and adjusting the dose of DOACs should be done if
necessary.
Antiarrhythmic agents. Some antiarrhythmic agents, such as
digoxin, quinidine, lignocaine and procainamide, potentially inter-
act with ABs.64–75 Quinidine and lignocaine are CYP3A4 substrates
and therefore macrolides may inhibit their degradation and in-
crease their bioavailabilities.64,65 The renal clearance of procaina-
mide and digoxin is inhibited by trimethoprim.66,67,72,73 The
mechanism of interaction is inhibition of tubular secretion via in-
hibition of the renal organic cation transporter because they
are substrates of the transporter.66,67,72,73 Consequently, blood
concentrations of these drugs are increased.66,67,72,73 Digoxin is a
substrate of the P-gp transporter.68–71 Clarithromycin could ele-
vate the AUC of digoxin, which may cause toxicities.68–71 Since
quinidine, lignocaine, digoxin and procainamide are drugs with an
NTI, avoiding ABs that can lead to DDIs with these drugs is recom-
mended.76,77 However, if their co-prescription is necessary, thera-
peutic drug monitoring (TDM) of these antiarrhythmic agents is
strongly recommended.77
Respiratory diseases
Medication for obstructive airways diseases
One of the most prevalent comorbidities in COPD is asthma.14
Some anti-asthma drugs, such as methylprednisolone, montelu-
kast, loratadine, roflumilast and theophylline, are substrates of
CYP3A4 and/or the P-gp transporter and have been shown to inter-
act with macrolides.78–87 Hence, one might consider other ABs for
combination with asthma drugs, or closely monitor patients, espe-
cially in the case of theophylline, which is an NTI drug.88 As theo-
phylline is also metabolized by CYP1A2,89 ciprofloxacin (a CYP1A2
potent inhibitor) should be avoided.90–97
Antimycobacterial agents
Tuberculosis and COPD share comparable risk factors and there-
fore can co-occur in individuals, particularly elderly patients.98
Rifampicin and rifabutin (antimycobacterial agents) work as po-
tent inducers of hepatic and intestinal CYP enzymes.99 They can
markedly reduce the activities of clarithromycin, doxycycline and
trimethoprim/sulfamethoxazole by causing their rapid elimin-
ation.100–104 Since rifampicin also exhibits other AB properties,
such as activity against MRSA in combination with other drugs,
rationalizing antimicrobial therapy should be considered accord-
ingly.105 Alternative ABs for treating COPD are also recommended
to reduce the risk of treatment failures.
Moxifloxacin might be an alternative AB for clarithromycin,
doxycycline and trimethoprim/sulfamethoxazole owing to its
moderate or weak interaction with rifampicin.106–109 Moxifloxacin
is not metabolized by CYP450 and its interacting mechanisms with
rifampicin might be facilitated by induction of other enzymes, such
as uridine diphosphate-glucuronosyltransferases and sulfotrans-
ferases.106–109
Rifabutin and rifampicin are CYP substrates. Rifabutin is a
CYP3A4 substrate, and therefore macrolides may increase
its serum concentration and enhance the risk of related
ADR.101,110,111 Another study reported that rifampicin concentra-
tions in blood are moderately elevated by co-trimoxazole.104 It
was assumed that the interaction was facilitated by inhibition of
mixed-function oxidases, which are responsible for metabolizing
rifampicin.104 Thus, considering alternative ABs or monitoring
the clinical and biochemical parameters for rifampicin-related
hepatotoxicity is suggested when rifampicin and co-trimoxazole
are combined.
It should be mentioned that not all the drugs for atypical
Mycobacterium spp. were included in this review because selection
was limited to ABs that are used frequently among COPD patients.
For drugs outside the scope of this review, other references (e.g.
statements of product characteristics) need to be considered.
Neurological disorders
Anti-Parkinson’s drugs
Bromocriptine and cabergoline (dopamine agonists) are substrates
of CYP3A4 and/or the P-gp transporter.112,113 Co-prescription of
these drugs with clarithromycin and erythromycin may produce
major interactions and therefore might lead to toxicities.112,113
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if this is not possible, adjusting the dose of these Parkinson’s medi-
cations and closely monitoring side effects are needed.
Antiepileptic drugs
Carbamazepine, phenytoin and phenobarbital can stimulate the
activity of a variety of CYP (CYP1A2/2C9/3A4) and glucuronyl trans-
ferase enzymes, which results in multiple DDIs with other sub-
strates for these enzymes.114–116 Carbamazepine and phenytoin
were reported to reduce the half-life of doxycycline by stimulating
the hepatic metabolism of doxycycline.117 It is suggested that an
alternative AB should be considered or that the dose of antiepilep-
tic drugs should be adjusted while monitoring the AB activity of
doxycycline.
Carbamazepine and phenytoin are substrates of CYP1A2/3A4
and CYP2C8, respectively. A CYP1A2/3A4 inhibitor (ciprofloxacin)
and a CYP2C8 inhibitor (trimethoprim) were reported to increase
the bioavailability of carbamazepine and phenytoin, respective-
ly.116–119 Moreover, phenytoin is an NTI drug and therefore avoid-
ing using trimethoprim concomitantly or performing TDM of
phenytoin is recommended when this DDI is not avoidable.120
Ciprofloxacin was reported to increase the AUC of carbamaze-
pine by .50%.118 Although it is not clear whether carbamazepine
can be considered to be an NTI drug, a rising carbamazepine
plasma concentration because of this DDI needs special cau-
tion.121 Dose adjustment and TDM of carbamazepine are sug-
gested to diminish potential toxicities.
Depression and psychiatric disorders
Depression and psychiatric disorders are common among COPD
patients.14 Some antidepressant (trazodone), anxiolytic (buspir-
one) and antipsychotic (quetiapine, and pimozide) drugs are
CYP3A4 substrates and therefore might trigger clinically relevant
DDIs with ABs.122–125 Erythromycin and clarithromycin increased
the AUCs of these drugs substantially.122–125 Considering alterna-
tive ABs or adjusting the dose of substrates and monitoring related
side effects is the way to control potential ADR.
CYP3A4 is also responsible for metabolizing diazepam, in add-
ition to CYP2C19.126 Ciprofloxacin was reported to decrease diaze-
pam clearance moderately by inhibiting CYP3A4 activity.127
Monitoring diazepam-related side effects can therefore be consid-
ered when this combination is prescribed.
Ciprofloxacin is also a potent CYP1A2 inhibitor.128 Therefore,
metabolism of an atypical antipsychotic, clozapine, a CYP1A2 sub-
strate with an NTI, can be altered by ciprofloxacin, which produces
a significant increase in clozapine serum concentration.129,130
Replacing ciprofloxacin or TDM of clozapine is an option that can be
chosen in managing this DDI.
Dyspepsia
Drugs containing metal cations (e.g. antacids, sucralfate and bis-
muth salts) produced chemical interactions with some ABs, such
as oral tetracyclines (e.g. tetracycline, doxycycline) and fluoroqui-
nolones (e.g. ciprofloxacin, moxifloxacin).131–144 Tetracyclines
have a strong tendency to form chelates due to their structural
features, which include many chelation sites.145 Meanwhile, fluo-
roquinolones have two main sites of metal chelation: 4-keto oxy-
gen and 3-carboxylic acid groups.146
The formation of metal ion chelation complexes decreases ab-
sorption of tetracycline and fluoroquinolones, and this reduced
bioavailability may lead to ineffectiveness of these ABs.131–144
Therefore, it is recommended that their combination should be
avoided by replacing tetracyclines and fluoroquinolones with an-
other AB, e.g. amoxicillin or amoxicillin/clavulanic acid. It was
reported that antacids did not affect the bioavailability of amoxicil-
lin and amoxicillin/clavulanic acid when they were co-adminis-
tered.136 If replacement of the AB is not possible, replacement of
antacids, sucralfate or bismuth salts with a proton pump inhibitor
(PPI) is also favoured. Another alternative is to separate adminis-
tration by using quinolone or tetracycline at least 2 h before or 6 h
after the dyspepsia drugs.
When considering a PPI, lansoprazole may not be the best alter-
native as it is partly metabolized by CYP3A4 and has been found to
interact with clarithromycin.147
HIV
HIV-positive patients have an 50% higher risk of developing
COPD than HIV-negative patients.148 Thus, the risk of co-
prescriptions for treating these chronic conditions may also be
high. A protease inhibitor (saquinavir) and NRTIs (didanosine and
lamivudine) were found to clinically interact with ABs.149–153
Didanosine is very acid sensitive, and therefore didanosine for-
mulations are supplemented with buffering mixtures containing
magnesium hydroxide, dihydroxyaluminium sodium carbonate
and sodium citrate to prevent hydrolysis by gastric acid.149 These
metal ions may form chelation complexes with quinolones and re-
duce their serum concentration.149,150 Two studies confirmed the
didanosine and ciprofloxacin interaction, and recommended that
when co-administration cannot be avoided, ciprofloxacin must be
given at least 2 h before didanosine.149,150
Trimethoprim/sulfamethoxazole may inhibit clearances of di-
danosine and lamivudine by competitively hindering their renal se-
cretion.152,153 Consequently, AUCs of didanosine and lamivudine
are elevated moderately.152,153 Monitoring of the presumed side
effects should be performed.
Saquinavir is metabolized by CYP3A4 and the presence of
erythromycin increased its AUC by almost 100%.151 Choosing an
alternative AB or adjusting the dose of saquinavir while monitoring
toxicities can be considered as a means of managing this DDI.
Other potential clinically significant DDIs
Some other drugs that have indications for comorbidities in COPD
patients were found to interact with ABs. Some individual drugs of
different classes (e.g. voriconazole and vinorelbine) are metabo-
lized by CYP3A4.154–182 Therefore, their metabolism is interfered
with by CYP3A4 inhibitors (macrolides).154–182 Other drugs are
CYP1A2 substrates (e.g. ropivacaine and tizanidine) and therefore
potent inhibitors of CYP1A2, such as quinolones, significantly alter
their metabolism and elevate their bioavailabilities.164,183–185
Others are CYP2C8 substrates (e.g. loperamide for diarrhoea) and
therefore trimethoprim (a potent CYP2C8 inhibitor) inhibits their
clearance and increases their AUC values.186,187 Some drugs
containing metal cations (e.g. Fe, Zn, Ca) should be avoided or
administered with a separation of at least 2 h from quinolones and
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drug transporters. A uricosuric agent (probenecid) interacts mod-
erately with ciprofloxacin via competitive inhibition of organic
anion transporters in renal tubules.194,195 Moreover, linezolid,
which is a substrate of the P-gp transporter, can potentially pro-
duce clinically significant interaction with P-gp inhibitors
(macrolides).196
DDIs related to NTIs
Some ABs may interact with NTI drugs and therefore can produce
serious ADRs. The NTI drugs in this review include CYP3A4 sub-
strates (theophylline, ketamine, everolimus, tacrolimus, halofan-
trine, lignocaine, quinidine, voriconazole, carbamazepine, warfarin,
cyclosporine, colchicine, phenprocoumon/acenocoumarol);
CYP1A2 substrates (theophylline, carbamazepine, clozapine, tiza-
nidine); CYP2C9 substrates and drugs sensitive to alterations in the
normal gut flora (warfarin, phenprocoumon/acenocoumarol); a
CYP2C8 substrate (phenytoin); substrates of the P-gp transporter




This study outlines the possible DDIs related to frequently pre-
scribed ABs in COPD patients from clinical and observational stud-
ies. We only included well-designed studies (2 points) since they
provide more valid evidence than studies without a control or com-
parison group (0 or 1 point). DDIs based on case reports or hypoth-
eses may lead to unnecessary warnings if these are not confirmed
by well-designed studies. One classic example of this point is ABs
and oral contraceptive interactions; many cases of unintended
pregnancies were reported after ABs were prescribed to women
on oral contraceptives, which attracted much attention from
health practitioners.198,199 After scientific evidence from clinical
and pharmacokinetic studies has consistently and repeatedly
failed to support such interaction, the warning about DDIs be-
tween hormonal contraception and non-rifampicin ABs has finally
been cancelled in related guidelines.199
Mechanisms of DDI
A DDI of potential clinical significance between an AB and a co-
administered medication may occur in two situations: (i) the
co-administered drug influences the absorption, distribution, me-
tabolism and elimination (ADME) of the AB; and (ii) the AB influen-
ces the ADME of the co-administered medication. When the AB
acted as a substrate, some co-administered drugs reduced the
blood concentration of the AB and led to failure of the AB treat-
ment to reduce COPD exacerbations. Other co-administered drugs
increased the blood concentration of the AB, which could result in
the termination of AB use because of an ADR, and therefore
acted against the control of infection. Acting as inhibitors, ABs
could also increase the blood concentrations of co-administered
drugs, which may also produce an ADR and lead to termination
of co-administered drugs, and therefore may lead to failure of
treatment of comorbidities. Thus, DDIs related to ABs may hinder
effective infection control and exacerbation management among
COPD patients as well as treatment of comorbidities in COPD.
Comorbidities among COPD patients
The impact of comorbidities on quality of life in COPD patients is
well reported; however, potential drug interactions between
drugs for these comorbidities and ABs used for COPD have
received little specific attention. From this review, we found
that many drugs (e.g. those used for heart and circulatory sys-
tem diseases) should not be co-administered with related ABs,
and other actions are necessary, such as dose adjustment,
choosing an alternative drug and monitoring ADRs. These drug
interactions may not only influence treatment options for clinic-
al practitioners but also influence treatment effects for both
COPD and comorbidities.
Information collected in this review can be used as input to
improve the sensitivity and specificity of DDI alert systems.
Moreover, this study may also be attractive for researchers
in this field who may take into account the availability of high-
quality studies when evaluating the evidence for many poten-
tial interactions.
Special warning for NTI drugs
We found that some NTI drugs might potentially interact with ABs.
Because of the narrow separation between effective and toxic dos-
ing of these drugs, a small alteration of their pharmacokinetic
parameters can produce fatal consequences.88,120 Therefore,
combination with particular ABs that have an ability to inhibit their
clearance pathways should be avoided if possible. However, if the
benefits of combination outweigh the potential side effects, dose
adjustment and performing TDM of the NTI drugs are strongly
recommended.
Limitations
Some limitations of this review are worth mentioning. First, al-
though we reviewed a significant part of the literature, we did not
include all sources that might indicate relevant DDIs, such as case
reports, summary of product characteristics and theoretical
hypotheses. As a result, we did not find some DDIs that are consid-
ered serious and clinically highly relevant, such as QT-interval pro-
longing interactions for combinations of macrolides with other QT-
prolonging drugs or the risk of pseudotumour cerebri in the case of
combinations of doxycycline with vitamin A analogues.200,201 Such
interactions are commonly found as case reports, as it is unethical
to design studies to confirm these serious risks in clinical studies.
However, for some DDIs it is possible to study the clinical manifest-
ation of a potential DDI in an observational study using real-world
drug utilization data.202 Secondly, selection of the ABs included in
this review was based on their frequent use in COPD and therefore
information for other ABs used for COPD comorbidities, such as
atypical Mycobacterium spp., is limited, and this may restrict the
scope of application of this review. Thirdly, due to limited compara-
tive analyses for several specific DDIs included in this review, it
may be difficult to make recommendations for a specific situation.
Our classification of DDI levels only offers a general consideration.
The specific impact of a DDI is determined by many variables, such
as different doses and formulations and the comorbidities of
patients. Therefore, case-by-case analysis is important in clinical
practice and a drug interaction handbook such as Stockley’s Drug
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Conclusions
Clinically significant DDIs related to ABs may involve a wide range
of indicated drugs to treat comorbidities in COPD. Clinicians should
pay attention to these drug interactions when prescribing ABs in
order to reduce the frequency and severity of exacerbations in
COPD patients and take necessary actions to ensure therapeutic
effect and safety of patients. This study may contribute to better
prescribing of ABs to COPD patients with comorbidities where po-
tentially interacting drug combinations may be used. Furthermore,
the information may highlight gaps in scientific knowledge about
potential adverse effects from DDIs.
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